Operating income for the fiscal year ending January 2026 was a loss of 3,794 million JPY, and net income was a loss of 3,842 million JPY, worsening by 278 million JPY and 960 million JPY year-over-year respectively. Approximately 16.2 billion JPY of growth capital was secured through new share issuance and other means.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4592","jir_company_name":"SanBio Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-25","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4592-20260325-01.pdf","jir_short_summary":"Operating income for the fiscal year ending January 2026 was a loss of 3,794 million JPY, and net income was a loss of 3,842 million JPY, worsening by 278 million JPY and 960 million JPY year-over-year respectively. Approximately 16.2 billion JPY of growth capital was secured through new share issuance and other means.","jir_summary":"### FY Ending January 2026 Earnings Report\nIn the consolidated income statement for the fiscal year ending January 2026, research and development expenses amounted to 2,678 million JPY (Year-over-Year +321 million JPY), and business expenses were 3,794 million JPY (Year-over-Year +278 million JPY). Operating income was a loss of 3,794 million JPY, and net income was a loss of 3,842 million JPY, both declining compared to the prior year. On the consolidated balance sheet, approximately 16.2 billion JPY in growth capital was secured through new share issuance and other means, resulting in a significant increase in cash and deposits to 15,083 million JPY. Total assets reached 15,621 million JPY, and total net assets stood at 13,604 million JPY.\n\n### Earnings Guidance and Growth Strategy for the Current Fiscal Year\nFor the fiscal year ending January 2027, earnings guidance projects research and development expenses of 4,110 million JPY, business expenses of 5,625 million JPY, operating income as a loss of 5,625 million JPY, and net income as a loss of 5,635 million JPY. Although continued losses are forecasted, recording of business revenue is anticipated following the drug price listing of Akugo\u00ae. As cornerstones of the growth strategy, SanBio aims to establish Japan as its mother base, realize its U.S. operations, and achieve success with its stroke treatment drug, targeting global leadership in regenerative medicine. Marketing and public relations activities, as well as patient support systems, are being further developed.","jir_financial_highlights":"Research and Development Expenses: 2,678 million JPY (Year-over-Year +321 million JPY)\nBusiness Expenses: 3,794 million JPY (Year-over-Year +278 million JPY)\nOperating Income: \u25b23,794 million JPY (Year-over-Year \u25b2278 million JPY)\nNet Income Attributable to Owners of Parent: \u25b23,842 million JPY (Year-over-Year \u25b2960 million JPY)\nCash and Deposits: 15,083 million JPY (Compared to previous fiscal year-end +12,162 million JPY)\nTotal Assets: 15,621 million JPY (Compared to previous fiscal year-end +12,174 million JPY)\nTotal Net Assets: 13,604 million JPY (Compared to previous fiscal year-end +11,842 million JPY)","jir_category":"","jir_hashtags":"#SanBio, #EarningsPresentation, #RegenerativeMedicine","jir_key_figures":"Operating Income: \u25b23,794 million JPY (Year-over-Year \u25b2278 million JPY)\nNet Income Attributable to Owners of Parent: \u25b23,842 million JPY (Year-over-Year \u25b2960 million JPY)\nCash and Deposits: 15,083 million JPY (Compared to previous fiscal year-end +12,162 million JPY)","jir_meta_title":"SanBio FY Ending January 2026 Earnings Presentation | Operating Income \u25b23,794 Million JPY, Approximately 16.2 Billion JPY Growth Capital Secured","jir_meta_description":"SanBio Inc.'s FY ending January 2026 earnings presentation. Operating income was a loss of 3,794 million JPY, net income a loss of 3,842 million JPY. Approximately 16.2 billion JPY growth capital was secured through new share issuance and other means, aiming to become a global leader in regenerative medicine.","jir_og_title":"SanBio FY Ending January 2026 Earnings Presentation | Approximately 16.2 Billion JPY Growth Capital Secured","jir_og_description":"Operating income loss of 3,794 million JPY, net income loss of 3,842 million JPY. Growth strategy announced with a focus on Akugo\u00ae\u2019s drug price listing.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":9416,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-36453","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n